Pharmaceuticals News & Press Release Distribution

Ribo Discloses Positive Data from Vortosiran Phase 2a Trial - World's First Clinical Data on siRNA-Mediated FXI Inhibition Following Multiple Dosing in Patients with Coronary Artery Disease

SHANGHAI and MOLNDAL, Sweden, July 22, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo") today announce at China Pharmaceutical Innovation Conference (CPIC) in Shanghai, the positive results fro...

2026-07-22 20:28 4766

Tikva Allocell Closes $8 Million Series A Financing to Advance Engineered EBV-Specific T-Cell Therapy for Solid Tumors

Funding will support completion of IND-enabling activities and planned year-end IND submission for TAVST01, Tikva's lead off-the-shelf CAR-T candidate targeting B7-H3-positive solid tumors SINGAPORE, July 22, 2026 /PRNewswire/ -- Tikva Allocell Pte. Ltd.

2026-07-22 19:03 3986

Gene Solutions Showcases Global Evidence and Responsible Innovation in Prenatal and Women's Genomic Health at ISPD 2026

As a Premier Partner, Gene Solutions presented Asia-led real-world evidence from large-scale NIPT-integrated carrier screening, alongside advances in AI-enabled pregnancy-risk assessment and minimally invasive molecular approaches to women's health. SINGAPORE, July 22, 2026 /PRNewswire/ -- Gene ...

2026-07-22 11:59 3933

Gene Solutions Showcases Global Evidence and Responsible Innovation in Prenatal and Women's Genomic Health at ISPD 2026

China Pharma Holdings, Inc. Comments on Unusual Market Activity

HAIKOU, China, July 21, 2026 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma" or the "Company"), a fully-integrated specialty pharmaceuticals company in China, today announced that, in view of the unusual market activity in the common stock of China Pharma on July...

2026-07-22 04:00 4134

The Second Battlefield for Solid Tumor CAR-T: A Global Race in the Intracranial Arena -- Who Is Leading?

T-MAXIMUM PHARMACEUTICAL Inc's Universal CAR-T First-in-Human Data to Debut at the World Conference on Lung Cancer BEIJING, July 21, 2026 /PRNewswire/ -- Recently, the 2026 World Conference on Lung Cancer (WCLC) released a set of abstracts that drew notable industry attention: preliminary first-...

2026-07-21 20:30 3408

Alebund Pharmaceuticals Announces First Participant Randomized and Dosed in Global Phase IIb Multi-Regional Clinical Trial of AP306 for Hyperphosphatemia

SHANGHAI, July 21, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that the first participant has been randomized and dosed in the global Phase IIb multi-regional clinical trial of...

2026-07-21 19:00 3608

Takeda's Dengue Vaccine (TAK-003) Becomes India's First Approved Dengue Vaccine, Bringing Prevention to One of the World's Most At-Risk Populations

* The approval comes at a critical time for public health, as reported dengue cases in India have increased 11-fold in the past two decades[1] * Takeda's dengue vaccine (TAK-003) is the most extensively studied dengue vaccine, with long-term data demonstrating sustained protection against deng...

2026-07-21 16:41 3784

Takeda's Dengue Vaccine (TAK-003) Becomes India's First Approved Dengue Vaccine, Bringing Prevention to One of the World's Most At-Risk Populations

Rege Nephro Secures approximately US$10.6 Million to Advance RN-014 Toward Commercialization

Financing will support development of RN-014 and RN-032 and continued expansion of the company's kidney disease pipeline KYOTO, Japan, July 21, 2026 /PRNewswire/ -- Rege Nephro Co., Ltd. ("Rege Nephro"), a clinical-stage biotechnology company focused on iPS cell-based kidney regenerative medicin...

2026-07-21 12:00 3087

Rege Nephro Secures approximately US$10.6 Million to Advance RN-014 Toward Commercialization

ESMO 2026 | Mabwell to Present Latest Clinical Data on Nectin-4-targeting ADC 9MW2821 for Triple Negative Breast Cancer in Oral Presentation

SHANGHAI, July 20, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present the latest clinical study results of its novel Nectin‑4‑targeting ADC, 9MW2821, for triple‑negative breast cancer in an oral ...

2026-07-21 11:50 3593

SuanNutra, Parent Company of Monteloeder and a Carbyne Equity Partners Portfolio Company, Expands Product Portfolio with Specialty Natural Ingredients Businesses from IFF

MADRID, July 20, 2026 /PRNewswire/ -- SuanNutra, the global science-backed ingredients group, today announced it has signed an agreement to acquire a portfolio of specialty natural ingredients businesses from IFF (NYSE: IFF). The transaction, backed by SuanNutra's majority shareholder Carbyne Equ...

2026-07-21 07:30 6780

SuanNutra, Parent Company of Monteloeder and a Carbyne Equity Partners Portfolio Company, Expands Product Portfolio with Specialty Natural Ingredients Businesses from IFF

Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress

MELBOURNE, Australia and INDIANAPOLIS, July 21, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") provides a market update on its commercial and operational performance for the quarter ended June 30, 2026 (Q2 2026). Q2 2026 Highlights[1] * Group revenue of US...

2026-07-21 06:52 6067

Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer

• First patient dosed in Phase 3 LUTEON[1] trial evaluating TLX250-Tx in relapsed or recurrent clear cell renal cell carcinoma (ccRCC). • LUTEON is the first Phase 3 study of a CAIX[2]-targeted radiopharmaceutical therapy in ccRCC MELBOURNE, Australia and INDIANAPOLIS, July 21, 2026 /PRNewswire...

2026-07-21 05:00 3835

PharmaBlock Convenes Global Industry Leaders in Zurich to Advance Green Chemistry for Sustainable Pharmaceutical Manufacturing

ZURICH, July 20, 2026 /PRNewswire/ -- As Europe experienced one of its hottest Junes on record, with prolonged heatwaves reinforcing the urgency of climate action, leaders from the pharmaceutical industry and academia gathered in Zurich for thePharmaBlock's 3rd Green Chemistry Symposium (GCS) to ...

2026-07-20 20:00 4421

PharmaBlock Convenes Global Industry Leaders in Zurich to Advance Green Chemistry for Sustainable Pharmaceutical Manufacturing

Lundbeck announces last patient randomized in DEEp OCEAN, a large Phase III trial in developmental and epileptic encephalopathies (DEEs)

* DEEp OCEAN is a global trial designed to evaluate the investigational molecule bexicaserin for the treatment of seizures associated with DEEs, a diverse group of childhood-onset epilepsies1 * Broadest pivotal trial to date, enrolling patients with a wide range of DEE syndromes, the majority...

2026-07-20 16:20 3584

Medtrum Advances 300U Tubeless Patch Pump Toward German Launch

Higher-capacity option expands the TouchCare Nano System and supports Medtrum's continued growth in Europe BERLIN, July 20, 2026 /PRNewswire/ -- Medtrum, a global diabetes technology company, today announced further progress toward the German launch of its 300-unit (300U) tubeless patch pump, fo...

2026-07-20 15:05 2223

Antengene Announces Poster Presentation of ATG-022 and ATG-037 at ESMO 2026

SHANGHAI and HONG KONG, July 20, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...

2026-07-20 15:00 3675

Fostering new opportunities in the Greater Bay Area and Asia's Pharmaceutical Industry

SHANGHAI, July 20, 2026 /PRNewswire/ -- Following the landmark success of CPHI & PMEC China in June 2026, which welcomed an unprecedented gathering of industry professionals and fostered pivotal connections across the pharmaceutical supply chain, attention now shifts to South China. Building on ...

2026-07-20 13:47 2624

Akeso Doses First Patient in Phase II Study of Novel TROP2/Nectin-4 Bispecific ADC (AK146D1) in Combination with Ivonescimab for Advanced NSCLC

HONG KONG, July 20, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that the first patient has been dosed in a Phase II clinical study (AK146D1-201) evaluating its internally developed TROP2/Nectin-4 bispecific antibody-drug conjugate (ADC), AK146D1, in combi...

2026-07-20 13:32 3659

Fostering new opportunities in the Greater Bay Area and Asia's Pharmaceutical Industry

SHANGHAI, July 20, 2026 /PRNewswire/ -- Following the landmark success of CPHI & PMEC China in June 2026, which welcomed an unprecedented gathering of industry professionals and fostered pivotal connections across the pharmaceutical supply chain, attention now shifts to South China. Building on ...

2026-07-20 12:52 3321

Fostering new opportunities in the Greater Bay Area and Asia's Pharmaceutical Industry

Neuronata-R retains conditional approval in South Korea

South Korea's Ministry of Food and Drug Safety (MFDS) updates the stem cell therapy's approval in May 2026 — as the developer works to resume supply and build a U.S. research base SEOUL, South Korea, July 19, 2026 /PRNewswire/ -- Patients with amyotrophic lateral sclerosis (ALS) in South Korea w...

2026-07-20 07:00 2576